(Q38009942)

English

Detection of previously unidentified metastatic disease as a leading cause of screening failure in a phase III trial of zibotentan versus placebo in patients with nonmetastatic, castration resistant prostate cancer

scientific article published on 12 May 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

26 August 2017

Detection of previously unidentified metastatic disease as a leading cause of screening failure in a phase III trial of zibotentan versus placebo in patients with nonmetastatic, castration resistant prostate cancer (English)

1 reference

Europe PubMed Central

PMC publication ID

26 August 2017

phase III clinical trial

0 references

0 references

prostate cancer

1 reference

based on heuristic

inferred from title

5

object named as

Karim Fizazi

1 reference

Europe PubMed Central

26 August 2017

PMC publication ID

Celestia Higano

8

object named as

Celestia S Higano

1 reference

Europe PubMed Central

PMC publication ID

26 August 2017

author name string

Evan Y Yu

1

1 reference

Europe PubMed Central

PMC publication ID

26 August 2017

Kurt Miller

2

1 reference

Europe PubMed Central

PMC publication ID

26 August 2017

Joel Nelson

3

1 reference

Europe PubMed Central

PMC publication ID

26 August 2017

Martin Gleave

4

1 reference

Europe PubMed Central

PMC publication ID

26 August 2017

Judd W Moul

6

1 reference

Europe PubMed Central

PMC publication ID

26 August 2017

Faith E Nathan

7

1 reference

Europe PubMed Central

PMC publication ID

26 August 2017

language of work or name

0 references

publication date

12 May 2012

1 reference

Europe PubMed Central

PMC publication ID

26 August 2017

Journal of Urology

1 reference

Europe PubMed Central

PMC publication ID

26 August 2017

188

1 reference

Europe PubMed Central

PMC publication ID

26 August 2017

1

1 reference

Europe PubMed Central

PMC publication ID

26 August 2017

103-109

1 reference

Europe PubMed Central

PMC publication ID

26 August 2017

Updates on therapeutic targets and agents in castration-resistant prostate cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3473078

6 September 2017

Disease and host characteristics as predictors of time to first bone metastasis and death in men with progressive castration-resistant nonmetastatic prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3473078

6 September 2017

New molecular targets in bone metastases.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3473078

6 September 2017

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3473078

6 September 2017

Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3473078

6 September 2017

Beyond PSA: utility of novel tumor markers in the setting of elevated PSA.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3473078

6 September 2017

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3473078

6 September 2017

Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3473078

6 September 2017

Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3473078

6 September 2017

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3473078

6 September 2017

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3473078

6 September 2017

New bone formation in an osteoblastic tumor model is increased by endothelin-1 overexpression and decreased by endothelin A receptor blockade

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3473078

28 September 2017

Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3473078

23 June 2018

Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3473078

23 June 2018

PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3473078

31 August 2018

Final safety and efficacy analysis of the specific endothelin A receptor antagonist zibotentan (ZD4054) in patients with metastatic castration-resistant prostate cancer and bone metastases who were pain-free or mildly symptomatic for pain: a double-

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3473078

31 August 2018

Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3473078

31 August 2018

Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3473078

31 August 2018

Expression of endothelin receptor a associated with prostate cancer progression

1 reference

https://pubmed.ncbi.nlm.nih.gov/22583636

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1016/J.JURO.2012.03.008

1 reference

Europe PubMed Central

PMC publication ID

26 August 2017

release_rubhir7cv5bnvhbbchebzmlsoa

1 reference

https://api.fatcat.wiki/v0/release/rubhir7cv5bnvhbbchebzmlsoa

24 November 2022

based on heuristic

mapped directly with Wikidata item

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

26 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

26 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38009942&oldid=2186392925"